Immunohistochemistry and the diagnosis of malignant mesothelioma
2001; Wiley; Volume: 38; Issue: 5 Linguagem: Inglês
10.1046/j.1365-2559.2001.01092.x
ISSN1365-2559
Autores Tópico(s)Soft tissue tumor case studies
ResumoHistopathologyVolume 38, Issue 5 p. 471-476 Immunohistochemistry and the diagnosis of malignant mesothelioma J E King, J E King Department of Histopathology, South Manchester University Hospitals NHS Trust, Manchester, UKSearch for more papers by this authorP S Hasleton, P S Hasleton Department of Histopathology, South Manchester University Hospitals NHS Trust, Manchester, UKSearch for more papers by this author J E King, J E King Department of Histopathology, South Manchester University Hospitals NHS Trust, Manchester, UKSearch for more papers by this authorP S Hasleton, P S Hasleton Department of Histopathology, South Manchester University Hospitals NHS Trust, Manchester, UKSearch for more papers by this author First published: 21 December 2001 https://doi.org/10.1046/j.1365-2559.2001.01092.xCitations: 16 Professor Hasleton Department of Histopathology, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Attanoos R, Dojcinov S, Webb R, Gibbs A. Antimesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000; 37 ; 224–231.DOI: 10.1046/j.1365-2559.2000.00981.x 2 Attanoos R, Goddard H, Gibbs A. Mesothelioma binding antibodies: thrombomodulin, OV632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996; 29 ; 209–215. 3 Attanoos R, Webb R, Gibbs A. CD 44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology 1997; 30 ; 260–263. 4 McCaughey W, Colby T, Battifora H et al. Diagnosis of diffuse malignant mesothelioma: Experience of a US/Canadian mesothelioma panel. Mod. Pathol. 1991; 4 ; 342–353. 5 Sahn S. Malignancy metastatic to the pleura. Clin. Chest Med. 1998; 19 ; 351–361. 6 Peto J, Hodgson J, Matthews F, Jones J. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345 ; 535–539. 7 Henderson D, Attwood H, Constance T, Shilkin K, Steele R. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct. Pathol. 1988; 12 ; 367–384. 8 Travis W, Colby T, Corrin B, Shimosato Y, Brambilla E. WHO international histological classification of tumours: histological typing of lung and pleural tumours. Springer Verlag, 1999. 9 Hasleton P. Pleural disease. In Hasleton PS ed. Spencer's pathology of the lung. New York: McGraw-Hill, 1996; 1131–1210. 10 Hasleton P & King J. Malignant pleural mesothelioma: Pathology and differential diagnosis. E. J. Pathol. 1999; 5 ; 991–1005. 11 Hasleton P & Hammar S. Malignant mesothelioma. Curr. Diagn. Pathol. 1996; 3 ; 153–164. 12 Legier J & Maddox JC. Immunohistochemical diagnosis of mesothelioma. In Jaurand MC and Bignon J eds. The mesothelial cell and mesothelioma. New York: Marcel Dekker, 1994; 103–119. 13 Mezger J, Lamerz R, Permanetter W. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. J. Thorac. Cardiovasc. Surg. 1990; 100 ; 860–866. 14 Sheibani K, Battifora H, Burke J, Rappaport H. Leu-M1 antigen in human neoplasms: an immunohistologic study of 400 cases. Am. J. Surg. Pathol. 1986; 10 ; 227–236. 15 Andrion A, Magnani C, Betta P et al. Malignant mesothelioma of the pleura: interobserver variability. J. Clin. Pathol. 1995; 48 ; 856–860. 16 Wick M. Immunophenotyping of malignant mesothelioma. Am. J. Surg. Pathol. 1997; 21 ; 1395–1398.DOI: 10.1016/s0098-1354(97)00013-6 17 Shah I, Salvatore J, Kummet T, Gani O, Wheeler L. Pseudomesotheliomatous carcinoma involving pleura and peritoneum: a clinicopathologic and immunohistochemical study of three cases. Ann. Diagn. Pathol. 1999; 3 ; 148–159. 18 Attanoos R & Gibbs A. Pathology of malignant mesothelioma. Histopathology 1997; 30 ; 403–418. 19 Riera J, Astengo-Osuna C, Longmate J, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced eptope retrieval. Am. J. Surg. Pathol. 1997; 21 ; 1409–1419.DOI: 10.1002/(sici)1522-2683(20000401)21:7 3.0.co;2-0 20 Ordóñez N. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Am. J. Clin. Pathol. 1999; 112 ; 75–89. 21 Cury P, Butcher D, Corrin B, Nicholson A. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J. Pathol. 1999; 189 ; 251–257.DOI: 10.1002/(sici)1096-9896(199910)189:2 3.0.co;2-f 22 Zhang P, Livolsi V, Brooks J. Malignant epithelioid vascular tumours of the pleura: Report of a series and literature review. Hum. Pathol. 2000; 31 ; 29–34. 23 Nappi O, Ritter J, Pettinato G, Wick M. Hemangiopericytoma: histopathological pattern or clinicopathologic entity? Semin. Diagn. Pathol. 1995; 12 ; 221–232. 24 Wang N, Huang S, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers. Cancer 1979; 44 ; 937–943. 25 Sheibani K, Shin S, Kezirian J, Weiss L. Ber-Ep4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma vs adenocarcinoma. Am. J. Surg. Pathol. 1991; 15 ; 779–784. 26 Morgan R, DeYoung B, McGaughy V, Niemann T. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999; 87 ; 390–394.DOI: 10.1002/(sici)1097-0142(19991225)87:6 3.0.co;2-4 27 Sheibani K, Batttifora H, Burke J. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu-M1 antigen. Am. J. Pathol. 1986; 123 ; 212–219. 28 Montag A, Pinkus G, Corson J. Keratin protein immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesothelioma: an immunoperoxidase study of 30 cases. Hum. Pathol. 1988; 19 ; 336–342. 29 Clover J, Oates J, Edwards C. Anticytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31 ; 140–143. 30 Ordóñez N. Value of cytokeratin 5/6 in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am. J. Surg. Pathol. 1998; 22 ; 1215–1221.DOI: 10.1016/s0098-1354(98)00025-8 31 Edwards C & Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed paraffin embedded material. J. Clin. Pathol. 1995; 48 ; 626–630. 32 Peralta-Soler A, Knudsen K, Jaurand M. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum. Pathol. 1995; 26 ; 1363–1369. 33 Han A, Peralta-Soler A, Knudsen K et al. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum. Pathol. 1997; 28 ; 641–645. 34 Leers M, Aarts M, Theunissen P. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998; 32 ; 209–216. 35 Bejarano P, Baughmann R, Biddinger P et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod. Pathol. 1996; 9 ; 445–452. 36 Di Loreto C, Puglisi F, Di Lauro V, Damante G, Beltrami C. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett. 1998; 124 ; 73–78.DOI: 10.1016/s0304-3835(97)00466-7 37 Ordóñez N. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and non-pulmonary adenocarcinoma. Am. J. Surg. Pathol. 2000; 24 ; 598–606.DOI: 10.1107/s0021889890013334 38 Sheibani K, Esteban J, Bailey A, Battifora H, Weiss L. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum. Pathol. 1992; 23 ; 107–116. 39 Donna A, Betta P-G, Chiodera P et al. Newly marketed tissue markers for malignant mesothelioma: Immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature of so-called antimesothelioma antibodies. Hum. Pathol. 1997; 28 ; 929–937. 40 Anderson T, Holmes E, Kosaka C et al. Monoclonal antibodies to human malignant mesothelioma. J. Clin. Immunol. 1987; 7 ; 254–261. 41 Ordóñez N. The value of antibodies 44–3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. A comparative study with other commonly used antibodies. Am. J. Surg. Pathol. 1997; 21 ; 1399–1408.DOI: 10.1016/s0142-9612(00)00043-0 42 Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn. Cytopathol. 1999; 20 ; 125–130.DOI: 10.1002/(sici)1097-0339(199903)20:3 3.3.co;2-m 43 Oates J & Edwards C. HBME-1, MOC-31, WT-1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36 ; 341–347.DOI: 10.1046/j.1365-2559.2000.00770.x 44 Law M, Ward F, Hodson M, Heard B. Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure. Thorax 1983; 38 ; 744–746. 45 Adams V, Unni K, Muhm J et al. Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 1986; 58 ; 1540–1551. 46 Antman K, Shemin R, Ryan L et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana–Faber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J. Clin. Oncol. 1988; 6 ; 147–153. 47 Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J. Clin. Oncol. 1989; 7 ; 1157–1168. 48 Manzini VdP, Brollo A, Franceschi S et al. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993; 72 ; 410–417. 49 Ishida T, Tateishi M, Kaneko S et al. Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immuno histochemical studies. J. Thorac. Cardiovasc. Surg. 1990; 100 ; 844–852. 50 Ro J, Chen J, Lee J et al. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992; 69 ; 376–386. 51 Fishback N, Travis W, Moran C et al. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994; 73 ; 2936–2945. 52 Matsui K, Kitagawa M, Miwa A. Lung carcinoma with spindle cell components: sixteen cases examined by immunohistochemistry. Hum. Pathol. 1992; 23 ; 1289–1297. 53 Enzinger F & Weiss S. Soft tissue tumours. St Louis: Mosby-Year Book, 1995. 54 Zeren H, Moran C, Suster S, Fishback N, Koss M. Primary pulmonary sarcomas with features of monophasic synovial sarcomas: a clinicopathological, immunohistochemical, and ultrastructural study of 25 cases. Hum. Pathol. 1995; 26 ; 474–480. 55 Nicholson A, Goldstraw P, Fisher C. Synovial sarcoma of the pleura and its differentiation from other primary pleural tumopurs: a clinicopathological and immunohistochemical review of three cases. Histopathology 1998; 33 ; 508–513. 56 Kannerstein M & Churg J. Desmoplastic diffuse malignant mesothelioma. Prog. Surg. Pathol. 1980; 2 ; 19–29. 57 Wilson G, Hasleton P, Chatterjee A. Desmoplastic malignant mesothelioma: a review of 17 cases. J. Clin. Pathol. 1992; 45 ; 295–298. 58 Colby T. Malignancies in the lung and pleura mimicking benign processes. Semin. Diagn. Pathol. 1995; 12 ; 30–44. 59 Henderson D, Shilkin K, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ. Am. J. Clin. Pathol. 1998; 110 ; 397–404. 60 Cantin R, Al-Jabi M, McCaughey W. Desmoplastic diffuse mesothelioma. Am. J. Surg. Pathol. 1982; 6 ; 215–222. 61 Moll R, Dhouailly D, Sun T-T. Expression of cytokeratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. Virchows Arch. B Cell Pathol. 1989; 58 ; 129–145. 62 Gotzos V, Vogt P, Celio M. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol. Res. Pract. 1996; 192 ; 137–147. 63 Doglioni C, Dei Tos A, Laurino L et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am. J. Surg. Pathol. 1996; 20 ; 1037–1046.DOI: 10.1002/(sici)1099-114x(199612)20:12 3.0.co;2-z 64 Klima M & Gyorkey F. Benign pleural lesions and malignant mesothelioma. Virchows Arch. A Pathol. Anat. Histol. 1977; 376 ; 181–193. 65 Scurry J & Duggan M. Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia. J. Clin. Pathol. 1999; 52 ; 535–537. 66 Battifora H & McCaughey W. Tumors of the serosal membranes. Washington DC: Armed Forces Institute of Pathology, 1994. 67 Hammar S, Bockus D, Remington F, Ka R. Mucin-positive mesotheliomas: a histochemical, immunohistochemical and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas. Ultrastruct. Pathol. 1996; 20 ; 293–325. Citing Literature Volume38, Issue5May 2001Pages 471-476 ReferencesRelatedInformation
Referência(s)